which reflects the continuation of softer demand for TAVR in 2025. While Edwards is expected to receive a substantial indication expansion for its Sapien 3 valve in mid-2025, we doubt this will ...

Edwards Lifesciences reported better-than-expected fourth-quarter sales, driven by its transcatheter aortic valve replacement (TAVR) devices, to finish 2024 on an upbeat but cautious note after a ...

Stifel analyst Rick Wise upgraded Edwards from Hold to Buy, raising the price forecast to $90 from $75. Wise suggests that recent conversations with six Transcatheter aortic valve replacement ...